Goldman Sachs Maintains Neutral on RXO, Raises Price Target to $20

Benzinga · 2d ago
Goldman Sachs analyst Jordan Alliger maintains RXO (NYSE:RXO) with a Neutral and raises the price target from $18 to $20.